REDWOOD CITY, Calif., Sept. 18, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation of clinical trial results on its hypoxia-activated prodrug, TH-302. The presentation will take place at the Joint 15th Congress of the European CanCer Organisation (ECCO) and the 34th Congress of the European Society for Medical Oncology (ESMO) being held September 20 to 24, 2009, in Berlin, Germany.
